By Bill Fisher | October 21st, 2020
That will probably be the next step. After phase 3 studies, once we are satisfied with the data set and we can prove that this drug slows the disease through amyloid clearing and tau is also lessened, then we can move to a prevention study. We can test healthy people and try using the drug to keep them healthy. Aducanumab has been only tested on people with mild cognitive impairment and hasn’t been tested on those in later stages of the disease. At that point, amyloid isn’t the only driving factor of the disease, so we are unsure if the treatment will be at all successful.